Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Tumour-associated splice variants of fibronectin are a major source of tumour-matrix associated targets and are proving very successful in the development of clinical agents to treat cancer. One of the first monoclonal antibodies to be produced to this target, murine BC-1, recognises a cryptic epitope in domain 7 of the B-form splice variant (EDB-FN). Antibody fragments based on this immunoglobulin (IgG) were unstable, but BC-1 humanisation provided an opportunity to produce a more stable single-chain Fv (scFv). The variable domains of the humanized BC-1 IgG were sub-cloned and constructed into a scFv (HuBC-1 scFv) which was successfully expressed in Escherichia coli. The scFv retained its conformationally-sensitive epitope recognition and demonstrated a good affinity to the target of around 50 nM as measured by ELISA, Surface Plasmon Resonance and Flow Cytometry. Furthermore, the scFv was thermostable and stable in serum allowing substantial localisation to human tumours grown in mouse xenograft models. This scFv could form the basis of future tumour-specific biopharmaceuticals. Copyright © 2012 Elsevier Inc. All rights reserved.


Nor Adzimah Johdi, Ruth Harman, Irene Sanjuan, Christina Kousparou, Nigel Courtenay-Luck, Mahendra P Deonarain. Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. Protein expression and purification. 2013 Mar;88(1):157-63

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 23291225

View Full Text